jeff on brr in 2006

Since we are delving back in time to look for clues to origins of partnerships, it might be interesting for many who had not listened at the time to this broadcast to do so now.


In this broadcast he mentions that the first successful in vivo testing was made public, probably the onset of the large players becoming aware of OBJ and hence so interesting to go back to.

In the end he is asked by the commentator what his expected timeline for deals would be and he answers that within the next 12 months a cosmetic partner or pharmaceutical deals should be aligned.
Bill Hoehnefeld was hired to oversee production and commercialisation in anticipation of those deals.

What happened?

OBJ obviously was taken up by much larger players than previously anticipated by management and henceforth became dependent on their lenghty timelines and schedules.


It is also a good way to understand more how inductive
delivery is working, as in non contact.
When comparing our technology to other research or devices using iontophoresis, it is remarkable that our technology avoids direct currents to the skin as it happens in iontophoresis applications but is fully reversable in its effects.

As I see it, OBJ got cought in something far bigger than the directors initially anticipated.
The market took this delay, due to slow timelines of global pharmas and companies, paired with the arrival of nebulous confidentiality driven anns, as a sign of non- performing when it comes to tangible outcomes.
That's where market is wrong and we should see the correction in this misperception soon.


http://www.brr.com.au/event/10150/deciphering-the-lingo-biotechs-forumbrobj-mr-jeffrey-edwards-director